<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d269">
    <sentence id="DDI-DrugBank.d269.s0" text="Inhibitors of CYP2D6;"/>
    <sentence id="DDI-DrugBank.d269.s1" text="poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .">
        <entity charOffset="21-31" id="DDI-DrugBank.d269.s1.e0" text="debrisoquin" type="drug"/>
        <entity charOffset="50-59" id="DDI-DrugBank.d269.s1.e1" text="carvedilol" type="drug"/>
        <entity charOffset="103-111" id="DDI-DrugBank.d269.s1.e2" text="quinidine" type="drug"/>
        <entity charOffset="114-123" id="DDI-DrugBank.d269.s1.e3" text="fluoxetine" type="drug"/>
        <entity charOffset="126-135" id="DDI-DrugBank.d269.s1.e4" text="paroxetine" type="drug"/>
        <entity charOffset="142-152" id="DDI-DrugBank.d269.s1.e5" text="propafenone" type="drug"/>
        <entity charOffset="263-272" id="DDI-DrugBank.d269.s1.e6" text="carvedilol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e1" id="DDI-DrugBank.d269.s1.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e2" id="DDI-DrugBank.d269.s1.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e3" id="DDI-DrugBank.d269.s1.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e4" id="DDI-DrugBank.d269.s1.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e5" id="DDI-DrugBank.d269.s1.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e0" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e1" e2="DDI-DrugBank.d269.s1.e2" id="DDI-DrugBank.d269.s1.p6"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e1" e2="DDI-DrugBank.d269.s1.e3" id="DDI-DrugBank.d269.s1.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e1" e2="DDI-DrugBank.d269.s1.e4" id="DDI-DrugBank.d269.s1.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e1" e2="DDI-DrugBank.d269.s1.e5" id="DDI-DrugBank.d269.s1.p9"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e1" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p10"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e2" e2="DDI-DrugBank.d269.s1.e3" id="DDI-DrugBank.d269.s1.p11"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e2" e2="DDI-DrugBank.d269.s1.e4" id="DDI-DrugBank.d269.s1.p12"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e2" e2="DDI-DrugBank.d269.s1.e5" id="DDI-DrugBank.d269.s1.p13"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s1.e2" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p14" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e3" e2="DDI-DrugBank.d269.s1.e4" id="DDI-DrugBank.d269.s1.p15"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e3" e2="DDI-DrugBank.d269.s1.e5" id="DDI-DrugBank.d269.s1.p16"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s1.e3" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p17" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s1.e4" e2="DDI-DrugBank.d269.s1.e5" id="DDI-DrugBank.d269.s1.p18"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s1.e4" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p19" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s1.e5" e2="DDI-DrugBank.d269.s1.e6" id="DDI-DrugBank.d269.s1.p20" type="effect"/>
    <negationtags>poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; been studied, &lt;/scope&gt; but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .</negationtags></sentence>
    <sentence id="DDI-DrugBank.d269.s2" text="Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer."/>
    <sentence id="DDI-DrugBank.d269.s3" text="Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.">
        <entity charOffset="53-85" id="DDI-DrugBank.d269.s3.e0" text="agents with b-blocking properties" type="group"/>
        <entity charOffset="137-145" id="DDI-DrugBank.d269.s3.e1" text="reserpine" type="drug"/>
        <entity charOffset="151-178" id="DDI-DrugBank.d269.s3.e2" text="monoamine oxidase inhibitors" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s3.e0" e2="DDI-DrugBank.d269.s3.e1" id="DDI-DrugBank.d269.s3.p0" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s3.e0" e2="DDI-DrugBank.d269.s3.e2" id="DDI-DrugBank.d269.s3.p1" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s3.e1" e2="DDI-DrugBank.d269.s3.e2" id="DDI-DrugBank.d269.s3.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s4" text="Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.">
        <entity charOffset="0-8" id="DDI-DrugBank.d269.s4.e0" text="Clonidine" type="drug"/>
        <entity charOffset="41-49" id="DDI-DrugBank.d269.s4.e1" text="clonidine" type="drug"/>
        <entity charOffset="56-88" id="DDI-DrugBank.d269.s4.e2" text="agents with b-blocking properties" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s4.e0" e2="DDI-DrugBank.d269.s4.e1" id="DDI-DrugBank.d269.s4.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s4.e0" e2="DDI-DrugBank.d269.s4.e2" id="DDI-DrugBank.d269.s4.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s4.e1" e2="DDI-DrugBank.d269.s4.e2" id="DDI-DrugBank.d269.s4.p2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s5" text="When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.">
        <entity charOffset="32-64" id="DDI-DrugBank.d269.s5.e0" text="agents with b-blocking properties" type="group"/>
        <entity charOffset="70-78" id="DDI-DrugBank.d269.s5.e1" text="clonidine" type="drug"/>
        <entity charOffset="105-120" id="DDI-DrugBank.d269.s5.e2" text="b-blocking agent" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s5.e0" e2="DDI-DrugBank.d269.s5.e1" id="DDI-DrugBank.d269.s5.p0" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s5.e0" e2="DDI-DrugBank.d269.s5.e2" id="DDI-DrugBank.d269.s5.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s5.e1" e2="DDI-DrugBank.d269.s5.e2" id="DDI-DrugBank.d269.s5.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s6" text="Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.">
        <entity charOffset="0-8" id="DDI-DrugBank.d269.s6.e0" text="Clonidine" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s7" text="Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.">
        <entity charOffset="0-11" id="DDI-DrugBank.d269.s7.e0" text="Cyclosporine" type="drug"/>
        <entity charOffset="46-57" id="DDI-DrugBank.d269.s7.e1" text="cyclosporine" type="drug"/>
        <entity charOffset="112-121" id="DDI-DrugBank.d269.s7.e2" text="carvedilol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s7.e0" e2="DDI-DrugBank.d269.s7.e1" id="DDI-DrugBank.d269.s7.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s7.e0" e2="DDI-DrugBank.d269.s7.e2" id="DDI-DrugBank.d269.s7.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s7.e1" e2="DDI-DrugBank.d269.s7.e2" id="DDI-DrugBank.d269.s7.p2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s8" text="In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.">
        <entity charOffset="38-49" id="DDI-DrugBank.d269.s8.e0" text="cyclosporine" type="drug"/>
        <entity charOffset="90-101" id="DDI-DrugBank.d269.s8.e1" text="cyclosporine" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s8.e0" e2="DDI-DrugBank.d269.s8.e1" id="DDI-DrugBank.d269.s8.p0"/>
    <negationtags>In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder &lt;scope&gt; &lt;cue&gt; no &lt;/cue&gt; adjustment was needed. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d269.s9" text="On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.">
        <entity charOffset="42-53" id="DDI-DrugBank.d269.s9.e0" text="cyclosporine" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s10" text="Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.">
        <entity charOffset="96-107" id="DDI-DrugBank.d269.s10.e0" text="cyclosporine" type="drug"/>
        <entity charOffset="165-174" id="DDI-DrugBank.d269.s10.e1" text="carvedilol" type="drug"/>
        <entity charOffset="205-216" id="DDI-DrugBank.d269.s10.e2" text="cyclosporine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s10.e0" e2="DDI-DrugBank.d269.s10.e1" id="DDI-DrugBank.d269.s10.p0" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s10.e0" e2="DDI-DrugBank.d269.s10.e2" id="DDI-DrugBank.d269.s10.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s10.e1" e2="DDI-DrugBank.d269.s10.e2" id="DDI-DrugBank.d269.s10.p2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s11" text="Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.">
        <entity charOffset="0-6" id="DDI-DrugBank.d269.s11.e0" text="Digoxin" type="drug"/>
        <entity charOffset="9-15" id="DDI-DrugBank.d269.s11.e1" text="Digoxin" type="drug"/>
        <entity charOffset="64-70" id="DDI-DrugBank.d269.s11.e2" text="digoxin" type="drug"/>
        <entity charOffset="76-85" id="DDI-DrugBank.d269.s11.e3" text="carvedilol" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s11.e0" e2="DDI-DrugBank.d269.s11.e1" id="DDI-DrugBank.d269.s11.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s11.e0" e2="DDI-DrugBank.d269.s11.e2" id="DDI-DrugBank.d269.s11.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s11.e0" e2="DDI-DrugBank.d269.s11.e3" id="DDI-DrugBank.d269.s11.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s11.e1" e2="DDI-DrugBank.d269.s11.e2" id="DDI-DrugBank.d269.s11.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s11.e1" e2="DDI-DrugBank.d269.s11.e3" id="DDI-DrugBank.d269.s11.p4"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s11.e2" e2="DDI-DrugBank.d269.s11.e3" id="DDI-DrugBank.d269.s11.p5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s12" text="Both digoxin and COREG slow AV conduction.">
        <entity charOffset="5-11" id="DDI-DrugBank.d269.s12.e0" text="digoxin" type="drug"/>
        <entity charOffset="17-21" id="DDI-DrugBank.d269.s12.e1" text="COREG" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s12.e0" e2="DDI-DrugBank.d269.s12.e1" id="DDI-DrugBank.d269.s12.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s13" text="Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.">
        <entity charOffset="35-41" id="DDI-DrugBank.d269.s13.e0" text="digoxin" type="drug"/>
        <entity charOffset="103-107" id="DDI-DrugBank.d269.s13.e1" text="COREG" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s13.e0" e2="DDI-DrugBank.d269.s13.e1" id="DDI-DrugBank.d269.s13.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s14" text="Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.">
        <entity charOffset="47-54" id="DDI-DrugBank.d269.s14.e0" text="Rifampin" type="drug"/>
        <entity charOffset="89-98" id="DDI-DrugBank.d269.s14.e1" text="carvedilol" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s14.e0" e2="DDI-DrugBank.d269.s14.e1" id="DDI-DrugBank.d269.s14.p0" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s15" text="Cimetidine increased AUC by about 30% but caused no change in Cmax.">
        <entity charOffset="0-9" id="DDI-DrugBank.d269.s15.e0" text="Cimetidine" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s16" text="Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.">
        <entity charOffset="0-23" id="DDI-DrugBank.d269.s16.e0" text="Calcium Channel Blockers" type="group"/>
        <entity charOffset="128-132" id="DDI-DrugBank.d269.s16.e1" text="COREG" type="brand"/>
        <entity charOffset="158-166" id="DDI-DrugBank.d269.s16.e2" text="diltiazem" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s16.e0" e2="DDI-DrugBank.d269.s16.e1" id="DDI-DrugBank.d269.s16.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s16.e0" e2="DDI-DrugBank.d269.s16.e2" id="DDI-DrugBank.d269.s16.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s16.e1" e2="DDI-DrugBank.d269.s16.e2" id="DDI-DrugBank.d269.s16.p2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s17" text="As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.">
        <entity charOffset="14-46" id="DDI-DrugBank.d269.s17.e0" text="agents with b-blocking properties" type="group"/>
        <entity charOffset="52-56" id="DDI-DrugBank.d269.s17.e1" text="COREG" type="brand"/>
        <entity charOffset="92-115" id="DDI-DrugBank.d269.s17.e2" text="calcium channel blockers" type="group"/>
        <entity charOffset="124-132" id="DDI-DrugBank.d269.s17.e3" text="verapamil" type="drug"/>
        <entity charOffset="137-145" id="DDI-DrugBank.d269.s17.e4" text="diltiazem" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e0" e2="DDI-DrugBank.d269.s17.e1" id="DDI-DrugBank.d269.s17.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e0" e2="DDI-DrugBank.d269.s17.e2" id="DDI-DrugBank.d269.s17.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e0" e2="DDI-DrugBank.d269.s17.e3" id="DDI-DrugBank.d269.s17.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e0" e2="DDI-DrugBank.d269.s17.e4" id="DDI-DrugBank.d269.s17.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e1" e2="DDI-DrugBank.d269.s17.e2" id="DDI-DrugBank.d269.s17.p4"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s17.e1" e2="DDI-DrugBank.d269.s17.e3" id="DDI-DrugBank.d269.s17.p5" type="advise"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s17.e1" e2="DDI-DrugBank.d269.s17.e4" id="DDI-DrugBank.d269.s17.p6" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e2" e2="DDI-DrugBank.d269.s17.e3" id="DDI-DrugBank.d269.s17.p7"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e2" e2="DDI-DrugBank.d269.s17.e4" id="DDI-DrugBank.d269.s17.p8"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s17.e3" e2="DDI-DrugBank.d269.s17.e4" id="DDI-DrugBank.d269.s17.p9"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s18" text="Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.">
        <entity charOffset="0-6" id="DDI-DrugBank.d269.s18.e0" text="Insulin" type="drug"/>
        <entity charOffset="16-28" id="DDI-DrugBank.d269.s18.e1" text="Hypoglycemics" type="group"/>
        <entity charOffset="31-63" id="DDI-DrugBank.d269.s18.e2" text="Agents with b-blocking properties" type="group"/>
        <entity charOffset="112-118" id="DDI-DrugBank.d269.s18.e3" text="insulin" type="drug"/>
        <entity charOffset="129-141" id="DDI-DrugBank.d269.s18.e4" text="hypoglycemics" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e0" e2="DDI-DrugBank.d269.s18.e1" id="DDI-DrugBank.d269.s18.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e0" e2="DDI-DrugBank.d269.s18.e2" id="DDI-DrugBank.d269.s18.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e0" e2="DDI-DrugBank.d269.s18.e3" id="DDI-DrugBank.d269.s18.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e0" e2="DDI-DrugBank.d269.s18.e4" id="DDI-DrugBank.d269.s18.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e1" e2="DDI-DrugBank.d269.s18.e2" id="DDI-DrugBank.d269.s18.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e1" e2="DDI-DrugBank.d269.s18.e3" id="DDI-DrugBank.d269.s18.p5"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e1" e2="DDI-DrugBank.d269.s18.e4" id="DDI-DrugBank.d269.s18.p6"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s18.e2" e2="DDI-DrugBank.d269.s18.e3" id="DDI-DrugBank.d269.s18.p7" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d269.s18.e2" e2="DDI-DrugBank.d269.s18.e4" id="DDI-DrugBank.d269.s18.p8" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s18.e3" e2="DDI-DrugBank.d269.s18.e4" id="DDI-DrugBank.d269.s18.p9"/>
    </sentence>
    <sentence id="DDI-DrugBank.d269.s19" text="Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.">
        <entity charOffset="30-36" id="DDI-DrugBank.d269.s19.e0" text="insulin" type="drug"/>
        <entity charOffset="46-58" id="DDI-DrugBank.d269.s19.e1" text="hypoglycemics" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d269.s19.e0" e2="DDI-DrugBank.d269.s19.e1" id="DDI-DrugBank.d269.s19.p0"/>
    </sentence>
</document>